News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Novartis AG MS Drug Linked to New Side Effect
April 14, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, April 14 (Reuters) - Fresh side-effect problems have emerged with Novartis AG's experimental oral multiple sclerosis (MS) drug FTY720, with doctors reporting a case of hemorrhaging focal encephalitis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Novartis
MORE ON THIS TOPIC
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
June 27, 2025
·
2 min read
·
Tristan Manalac
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
·
3 min read
·
Tristan Manalac
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
·
3 min read
·
Tristan Manalac
